Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have jointly patented aromatic acetylene derivatives acting as UDP-3-O-(R-3-hydroxymyristoyl)-N-acetylglucosamine deacetylase (LpxC) (bacterial) inhibitors and reported to be useful for the treatment of gram-negative bacterial infections.
Tricyclic fused pyrimidine compounds have been described in a Bristol Myers Squibb Co. patent as HER2 (erB2) and/or HER2 (erB2) mutant inhibitors with potential for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested cyclopenta-thieno-diazepine derivatives acting as GABA-A receptor subunit α2β2γ1 positive allosteric modulators (PAMs). As such, they are reported to be useful for the treatment of neurological disorders.
Crestone Inc. and the University of Colorado have reported efflux pump (bacterial) inhibitors potentially useful for the treatment of Gram-negative bacterial infections.
Abbisko Therapeutics Co. Ltd. has patented epidermal growth factor receptor (EGFR; HER1; erbB1) (mutant) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have discovered fibroblast growth factor receptor 2 (FGFR2) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Nhwa Pharmaceutical Co. Ltd. and Shujing Biopharma Co. Ltd. have synthesized oxaspiro derivatives acting as μ-opioid receptor agonists reported to be useful for the treatment of pain.
Beijing Tide Pharmaceutical Co. Ltd. proteolysis-targeting chimera (PROTAC) compounds comprising a ubiquitin ligase-binding moiety bonded to a protein phosphatase nonreceptor type 11 (PTPN11)-targeting moiety through a linker.
RSS